Abstract
CD40–CD40 ligand (CD40L) interaction is an important costimulatory signaling pathway in the crosstalk between T cells and antigen-presenting cells. This receptor–ligand system is known to be essential in eliciting strong cellular immunity. Here we demonstrate that murine lung cancer cells (3LLSA) transduced with the CD40L gene (3LLSA-CD40L) were rejected in syngeneic C57BL/6 mice, but grew in CD40-deficient mice to the same extent as control tumor cells. Immunohistochemical study showed that inflammatory cells, including CD4+, CD8+ T cells and NK cells, infiltrated into the inoculated 3LLSA-CD40L tumor tissue. Inoculation of 3LLSA-CD40L cells into mice resulted in the induction of 3LLSA-specific cytotoxic T-cell immunity, and the growth of parental 3LLSA tumors was inhibited when 3LLSA cells were inoculated into C57BL/6 mice mixed with 3LLSA-CD40L cells or when they were rechallenged 4 weeks after 3LLSA-CD40L cells were rejected. Furthermore, co-inoculation of interferon (IFN)-γ–transduced cells (3LLSA-IFNγ) with 3LLSA-CD40L cells enhanced the antitumor immunity efficiently in vivo. These results indicate that the in vivo priming with CD40L- and IFN-γ gene–transduced lung cancer cells is a promising strategy for inducing antitumor immunity in the treatment of lung cancer. Cancer Gene Therapy (2001) 8, 421–429
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lee CT, Chen HL, Carbone DP . Gene therapy for lung cancer Ann Oncol 1995 6: S61–63
Rosenberg SA . A new era for cancer immunotherapy based on the genes that encode cancer antigens Immunity 1999 10: 281–287
Wang RF, Rosenberg SA . Human tumor antigens for cancer vaccine development Immunol Rev 1999 170: 85–100
Villunger A, Strasser A . The great escape: is immune evasion required for tumor progression? Nat Med 1999 5: 874–875
Staveley OCK, Sotomayor E, Montgomery J, et al . Induction of antigen-specific T cell anergy: an early event in the course of tumor progression Proc Natl Acad Sci USA 1998 95: 1178–1183
Sotomayor EM, Borrello I, Tubb E, et al . Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 Nat Med 1999 5: 780–787
Banchereau J, Bazan F, Blanchard D, et al . The CD40 antigen and its ligand Annu Rev Immunol 1994 12: 881–922
Kawabe T, Naka T, Yoshida K, et al . The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation Immunity 1994 1: 167–178
Mackey MF, Gunn JR, Ting PP, et al . Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154 Cancer Res 1997 57: 2569–2574
Lanzavecchia A . Licence to kill Nature 1998 393: 413–414
Imaizumi K, Kawabe T, Ichiyama S, et al . Enhancement of tumoricidal activity of alveolar macrophages via CD40–CD40 ligand interaction Am J Physiol 1999 277: L49–L57
Riley V . Enzymatic determination of transmissible replicating factors associated with mouse tumors Ann NY Acad Sci 1963 100: 762–790
Silagi S . Control of pigment production in mouse melanoma cells in vitro. Evocation and maintenance J Cell Biol 1969 43: 263–274
Hasegawa Y, Bonavida B . Calcium-independent pathway of tumor necrosis factor–mediated lysis of target cells J Immunol 1989 142: 2670–2676
de Visser KE, Kast WM . Effects of TGF-β on the immune system: implications for cancer immunotherapy Leukemia 1999 13: 1188–1199
Salazar-Onfray F . Interleukin-10: a cytokine used by tumors to escape immunosurveillance Med Oncol 1999 16: 86–94
Huang M, Stolina M, Sharma S, et al . Non–small cell lung cancer cyclooxygenase-2–dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production Cancer Res 1998 58: 1208–1216
Walker PR, Saas P, Dietrich P-Y . Tumor expression of Fas ligand (CD95L) and the consequences Curr Opin Immunol 1998 10: 564–572
Gimmi CD, Morrison BW, Mainprice BA, et al . Breast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells Nat Med 1996 2: 1367–1370
Nakashima M, Sonoda K, Watanabe T . Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1 Nat Med 1999 5: 938–942
Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T . Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses Proc Natl Acad Sci USA 1996 93: 13119–13124
Seo N, Tokura Y, Takigawa M, Egawa K . Depletion of IL-10– and TGF-β–producing regulatory γδ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells J Immunol 1999 163: 242–249
Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Quaglino D . The immune system in the elderly: III. Innate immunity Immunol Res 1999 20: 117–126
van Kooten C, Banchereau J . Functions of CD40 on B cells, dendritic cells and other cells Curr Opin Immunol 1997 9: 330–337
Bianchi R, Grohmann U, Vacca C, Belladonna ML, Fioretti MC, Puccetti P . Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation J Immunol 1999 163: 2517–2521
Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G . Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T–T help via APC activation J Exp Med 1996 184: 747–752
Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK . CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40 J Exp Med 1993 178: 669–674
Esche C, Gambotto A, Satoh Y, et al . CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth Eur J Immunol 1999 29: 2148–2155
Costello RT, Gastaut J-A, Olive D . What is the real role of CD40 in cancer immunotherapy? Immunol Today 1999 20: 488–493
Hirano A, Longo DL, Taub DD, et al . Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand Blood 1999 93: 2999–3007
Biancone L, Cantaluppi V, Boccellino M, et al . Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma J Immunol 1999 163: 6201–6208
Nakajima A, Kodama T, Morimoto S, et al . Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7 J Immunol 1998 161: 1901–1907
Grossmann ME, Brown MP, Brenner MK . Antitumor responses induced by transgenic expression of CD40 ligand Hum Gene Ther 1997 8: 1935–1943
Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L . Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene–inserted tumor cells J Immunol 1993 150: 1458–1470
Snijders A, Kalinski P, Hilkens CMU, Kapsenberg ML . High-level IL-12 production by human dendritic cells requires two signals Int Immunol 1998 10: 1593–1598
Borges L, Miller RE, Jones J, et al . Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo J Immunol 1999 163: 1289–1297
Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP . Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response J Exp Med 1999 190: 125–133
Acknowledgements
The authors thank Keiko Shimamoto for her continuous technical assistance throughout our work. This work was supported by a grant-in-aid for COE Research from the Ministry of Education, Science, Sports and Culture of Japan and the 25th Aichi Cancer Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Noguchi, M., Imaizumi, K., Kawabe, T. et al. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-γ gene into lung cancer. Cancer Gene Ther 8, 421–429 (2001). https://doi.org/10.1038/sj.cgt.7700320
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700320
Keywords
This article is cited by
-
Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand
Cancer Immunology, Immunotherapy (2014)
-
Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model
BMC Pulmonary Medicine (2009)
-
Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas
Cancer Gene Therapy (2009)
-
Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer
Cancer Immunology, Immunotherapy (2006)
-
Prospects for CD40-directed experimental therapy of human cancer
Cancer Gene Therapy (2003)